The Lambert-Eaton myasthenic syndrome (LEMS) patient registry is a multicenter, longitudinal, observational program launched in European Union countries in May 2010 to increase knowledge about LEMS, better characterize its long-term clinical course, and to periodically collect long-term safety and efficacy information on LEMS-related treatments.

Sixty-nine patients have been enrolled (36 males, 32 females; mean age 61.5 years [27-84 years]), and 18 patients (26%) were diagnosed with an associated carcinoma.

At enrollment most patients demonstrate a profile of mild-to-moderate deficits in daily functioning, generally have good muscle strength but reduced deep tendon reflexes, frequent ataxia during walking, and some signs of autonomic dysfunction including dry mouth, bladder dysfunction, and constipation.

At the time of enrollment, the majority of patients (65%) were receiving amifampridine (either compounded 3,4-diaminopyridine [3,4-DAP; 22%] or 3,4-DAP phosphate, Firdapse® [43%]).